周二，研究公司Cowen开始对Centessa Pharmaceuticals (NASDAQ:CNTA)股票进行覆盖，给予该公司买入评级。这一决定得到了Centessa药物候选ORX750潜力的支撑，该药物正在开发用于治疗过度日间嗜睡。

Centessa Pharmaceuticals, founded from the merger of 10 biotech companies, is based on an asset-centric model, primarily ...

The last time I wrote about Centessa Pharmaceuticals plc (NASDAQ:CNTA), it was in a Seeking Alpha article entitled “Centessa: ...

根据最近的SEC文件显示，Centessa Pharmaceuticals plc (NASDAQ:CNTA)的首席执行官Saurabh Saha最近出售了55,000股普通股。这些股票以17.44美元的加权平均价格出售，价格范围在17.12美元至17.90美元之间。根据 InvestingPro ...

Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report)’s share price dropped 3.2% on Tuesday . The stock traded as low ...

In a report released yesterday, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Centessa Pharmaceuticals (CNTA – Research ...

We recently published an article entitled Why These 10 Stocks Jumped Yesterday. In this article, we are going to take a look ...

Current share price of US$16.75 suggests Centessa Pharmaceuticals is potentially 30% undervalued ...

Shares of NASDAQ:CNTA opened at $16.95 on Friday. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt ...

Centessa Pharmaceuticals ( (CNTA) ) has provided an update.

BOSTON and LONDON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...